These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 17507314)

  • 1. Spherical crystals of celecoxib to improve solubility, dissolution rate and micromeritic properties.
    Gupta VR; Mutalik S; Patel MM; Jani GK
    Acta Pharm; 2007 Jun; 57(2):173-84. PubMed ID: 17507314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preparation and physicochemical and preclinical evaluations of recrystallized celecoxib.
    Mutalik S; Usha N; Ranjith AK; Umesh S; Musmade P; Anup N
    PDA J Pharm Sci Technol; 2007; 61(5):362-74. PubMed ID: 18047175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spherical crystallization of celecoxib.
    Paradkar AR; Pawar AP; Chordiya JK; Patil VB; Ketkar AR
    Drug Dev Ind Pharm; 2002 Nov; 28(10):1213-20. PubMed ID: 12476867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of microcrystal formulation on in vivo absorption of celecoxib in rats.
    Nasr M
    AAPS PharmSciTech; 2013 Jun; 14(2):719-26. PubMed ID: 23543607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and characterization of microcrystals for enhanced dissolution rate of celecoxib.
    Lakshmi K; Reddy MP; Kaza R
    Curr Drug Discov Technol; 2013 Dec; 10(4):305-14. PubMed ID: 24074306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antisolvent precipitation technique: A very promising approach to crystallize curcumin in presence of polyvinyl pyrrolidon for solubility and dissolution enhancement.
    Sadeghi F; Ashofteh M; Homayouni A; Abbaspour M; Nokhodchi A; Garekani HA
    Colloids Surf B Biointerfaces; 2016 Nov; 147():258-264. PubMed ID: 27518458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of dissolution enhancement and bioavailability of poorly water soluble celecoxib by preparing stable amorphous nanoparticles.
    Liu Y; Sun C; Hao Y; Jiang T; Zheng L; Wang S
    J Pharm Pharm Sci; 2010; 13(4):589-606. PubMed ID: 21486533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physicochemical characterization and in vitro dissolution behaviour of celecoxib-beta-cyclodextrin inclusion complexes.
    Sinha VR; Anitha R; Ghosh S; Amita ; Kumria R; Bhinge JR; Kumar M
    Acta Pharm; 2007 Mar; 57(1):47-60. PubMed ID: 19839406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing various techniques to produce micro/nanoparticles for enhancing the dissolution of celecoxib containing PVP.
    Homayouni A; Sadeghi F; Varshosaz J; Garekani HA; Nokhodchi A
    Eur J Pharm Biopharm; 2014 Sep; 88(1):261-74. PubMed ID: 24952357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved bioavailability of aceclofenac from spherical agglomerates: development, in vitro and preclinical studies.
    Muatlik S; Usha AN; Reddy MS; Ranjith AK; Pandey S
    Pak J Pharm Sci; 2007 Jul; 20(3):218-26. PubMed ID: 17545107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of physico-mechanical properties of drug-excipients agglomerates obtained by crystallization.
    Maghsoodi M; Tajalli Bakhsh AS
    Pharm Dev Technol; 2011 Jun; 16(3):243-9. PubMed ID: 20175665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preparation, evaluation and need of spherical crystallization in case of high speed direct tabletting.
    Pandey S; Patil AT
    Curr Drug Deliv; 2014; 11(2):179-90. PubMed ID: 23848355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of spray-dried co-precipitate of amorphous celecoxib containing storage and compression stabilizers.
    Dhumal RS; Shimpi SL; Paradkar AR
    Acta Pharm; 2007 Sep; 57(3):287-300. PubMed ID: 17878109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Celecoxib-cyclodextrin systems: characterization and evaluation of in vitro and in vivo advantage.
    Nagarsenker MS; Joshi MS
    Drug Dev Ind Pharm; 2005 Jan; 31(2):169-78. PubMed ID: 15773284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advantages of celecoxib nanosuspension formulation and transformation into tablets.
    Dolenc A; Kristl J; Baumgartner S; Planinsek O
    Int J Pharm; 2009 Jul; 376(1-2):204-12. PubMed ID: 19426794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling of drug release from celecoxib-PVP-meglumine amorphous systems.
    Gupta P; Bansal AK
    PDA J Pharm Sci Technol; 2005; 59(6):346-54. PubMed ID: 16471422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparation and, in vitro, preclinical and clinical studies of aceclofenac spherical agglomerates.
    Usha AN; Mutalik S; Reddy MS; Ranjith AK; Kushtagi P; Udupa N
    Eur J Pharm Biopharm; 2008 Oct; 70(2):674-83. PubMed ID: 18606224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Formulation, characterization, and in vivo evaluation of celecoxib-PVP solid dispersion nanoparticles using supercritical antisolvent process.
    Ha ES; Choo GH; Baek IH; Kim MS
    Molecules; 2014 Dec; 19(12):20325-39. PubMed ID: 25486246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigation of atypical dissolution behavior of an encapsulated amorphous solid dispersion.
    Puri V; Dantuluri AK; Bansal AK
    J Pharm Sci; 2011 Jun; 100(6):2460-8. PubMed ID: 21246560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and evaluation of celecoxib porous particles using melt sonocrystallization.
    Paradkar A; Maheshwari M; Kamble R; Grimsey I; York P
    Pharm Res; 2006 Jun; 23(6):1395-400. PubMed ID: 16741659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.